Non-invasive cancer diagnostics are procedures used for the identification of cancer without incision in the body. Detection and treatment of cancer at early stages are important for long-term survival. Non-invasive cancer detection method is found to be an increasing choice of interest, owing to its painless or minimal pain method of diagnostic coupled with more accurate results. Molecular based diagnostic methods are expected to increase during the forecast period due to launches of new biomarker based detection methods. Moreover, factors like increasing incidence of cancer, increasing cancer screening rate, government initiatives, and emerging technologies such as next generation sequencing are expected to drive the market during the forecast period.
According to Cancer Research UK, currently no diagnostic tests are 100% sensitive in general practice. This suggests the unmet demand for novel diagnostic assay with more efficiency. The efficiency of molecular diagnostics for screening of blood and tissue sample for cancer detection fuels the research and development of biomarker based molecular diagnostic method, which can detect abnormalities in their early developmental cycle. Moreover, according to Genome Biology article published in 2017, the current research in non-invasive cancer detection are targeting two class of studies - the development of biomarkers for a specific cancer type and the characterization of circulating tumor DNA (ctDNA) for general cancer detection, without trying to predict specific cancer types. Such studies will help manufacturers to develop better cancer detection kits for molecular based diagnostics.
Non-Invasive Cancer Diagnostics Market Drivers
Increasing incidence of cancer is expected to be a major factor driving growth of non-invasive cancer diagnostics market. Cancer is a major factor impacting the world economy. For instance, according to the National Cancer Institute (NIH), cancer incidence was 439.2 per 100,000 individuals based on the cancer cases that occurred between 2011 and 2015. The same source estimated that rate of cancer survivors in the U.S. were 15.5 million, which is expected to increase to 20.3 million by 2026.
Increasing rate of cancer detection will also boost the non-invasive cancer diagnostics market growth. According to the U.S. Breast Cancer Surveillance Consortium (BCSC) researchers, the rate of cancer detection increased to 34.7 per 1,000 individuals in 2013, as compared to 25.3 per 1,000 individuals in 2005. Furthermore, governmental and non-governmental organizations are engaged in raising awareness for breast and cervical cancer as well as conducts screening programme. The National Institute for Health and Care Excellence (NICE) is involved in improving diagnosis rate by revising draft guideline for early cancer detection. Moreover, increasing cancer studies for cancer drug development will boost the non-invasive cancer diagnostics market growth. In 2016, NCI's Center to Reduce Cancer Health Disparities launched the National ‘Screen to Save’ Colorectal Cancer Outreach and Screening Initiative. The initiative was aimed at increasing colorectal cancer screening rate.
Non-Invasive Cancer Diagnostics Market - Regional Analysis
On the basis of region, the global non-invasive cancer diagnostics market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds a dominant position in the non-invasive diagnostics market, owing to increasing incidence of cancer, increasing technological advancement, better reimbursement scenario, and governmental initiatives for screening of cancer in early stages. For instance, the American Cancer Society Guidelines for the early detection of cancer offers various screening plans at different ages. For example, the guidelines suggest that women between the age of 40 and 44 must screen for breast cancer annually.
Non-Invasive Cancer Diagnostics Market – Competitive Landscape
Some of the key players operating in the global non-invasive cancer diagnostics market include Roche Diagnostics, Hologic Inc., Qiagen, Gen-Probe Inc., Digene Corporation, Abbott Molecular, IVDiagnostics, Laboratory Corporation of America Holdings, OncoCyte Corporation, Arquer Diagnostics Ltd. and Affymetrix Inc.
Increasing product launches as a part of organic strategies to rule the market is also the key factor contributing to the non-invasive cancer diagnostics market growth. For instance, in 2017, Natera, Inc., a company involved in non-invasive genetic testing, launched Sigatera, ctDNA technology based novel personalized approach for cancer detection. The advantage of the Signatera is that, it can target 16 or more patient–specific mutations. Moreover, technologies like spectroscopy is expected to be alternative for the liquid biopsy. For instance, in 2013, Medipex Ltd’s diagnostic device named ZedScan I, cervical cancer detection device received CE approval. Moreover, to enter China market, company announced strategic deal with MaxHealth Medicine Group in February 2018. Increasing pipeline products are also expected to boost the market growth. For instance, OncoCyte Corporation, is engaged in developing a confirmatory test for lung cancer via non-invasive liquid biopsy. Further, in 2016, Exosome Diagnostics, Inc. launched ExoDx Prostate (IntelliScore) test. The test uses genetic information from urine sample to evaluate patient risk for high grade prostate cancer. Laboratory Corporation of America Holdings, in 2016, launched Epi proColon, the first FDA-approved DNA based blood test for colorectal cancer screening with FDA approval.
The inorganic strategies by market players are continuously boosting the non-invasive cancer diagnostics market. For instance, in 2017, Lonza, a biopharmaceutical development and manufacturing company, acquired HanaBioMaed Life Sciences OU, a company dedicated to research and development, manufacturing and distribution of products for the exosome genome market. Through this acquisition, company will invest to develop exosome-based early-stage cancer screening and molecular diagnostic tests. In same year, CORE Diagnostics partnered with CellMax Life to introduce CellMax’s genetic cancer risk test and ctDNA-based liquid biopsy throughout India.
Non-Invasive Cancer Diagnostics Market Taxonomy
On the basis of technology, the non-invasive cancer diagnostics market is segmented into:
On the basis of cancer type, the non-invasive cancer diagnostics market is segmented into:
On the basis of region, the non-invasive cancer diagnostics market is segmented into:
Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:
In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.
Coherent Market Insights desk research is based on a principle set of research techniques:
Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:
Preliminary Data Mining
The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.
Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.
Coherent Statistical model
We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:
Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.
This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:
The primary research is conducted with the ecosystem players including, but not limited to:
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.[email protected]
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.